<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347886">
  <stage>Registered</stage>
  <submitdate>23/12/2011</submitdate>
  <approvaldate>6/01/2012</approvaldate>
  <actrnumber>ACTRN12612000024842</actrnumber>
  <trial_identification>
    <studytitle>Study of the outcome of patients with myeloma nephropathy on treatment with High Cut Off Haemodialysis (HCO-HD) in addition to chemotherapy at the Launceston General Hospital</studytitle>
    <scientifictitle>Study of the outcome of patients with myeloma nephropathy on treatment with High Cut Off Haemodialysis (HCO-HD) in addition to chemotherapy at the Launceston General Hospital</scientifictitle>
    <utrn>none</utrn>
    <trialacronym>HCO-HD</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To assess the effectiveness of high cut off haemodialysis (HCOD) daily for 8 hours until the serum free light chain level become below 500 mg/L, in addition to chemotherapy in light chain myltiple myeloma disease patients who present at the Launceston General Hospital (LGH) and treated conjointly by the the Haematology and Renal teams. The observation time is 12 months per patient following tretment.</interventions>
    <comparator>Patients with multiple myeloma and renal failure in compensatory phase who do not require dialysis.The observation time is at least12 months after completion of HCOD treatment for each patient with overall study period commencing from January 2009 till Dec 2013.</comparator>
    <control>Historical</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Myeloma active parameters: amount of light chain disease, bone marrow disease, lytic lesions, hypercalcaemia and renal function.

Assessed by serum free light chain, calcium level, bone marrow biopsy, radiological imaging and kidney function test</outcome>
      <timepoint>These will be assessed continously until the end of the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease outcome.
Assessed by overall disease remission status and survival rate</outcome>
      <timepoint>These will be assessed continously until the end of the study.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with multiple myeloma who have a light chain disease and renal impairment</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>patients who have low light chain disease that not cause renal impairment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate>1/08/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/08/2011</actualenddate>
    <samplesize>10</samplesize>
    <actualsamplesize>4</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>TAS</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Clifford Craig Medical Trust Fund</primarysponsorname>
    <primarysponsoraddress>Level 5 Launceston General Hospital Charles street Launceston, Tasmania 7250 Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Launceston General Hospital</fundingname>
      <fundingaddress>Charles street Launceston, Tasmania 7250 Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>School of Human Life Sciences</othercollaboratorname>
      <othercollaboratoraddress>University of Tasmania, 
Newnham Campus, Tasmania, 7249, Australia</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Light chain myeloma commonly associated with renal failure. Therefore, it is important to preserve the renal function early by applying high cut off haemodialysis. 
It is worthwhile to asses the effectiveness of the combination of high cut off haemodialysis (HCO-HD) in addition of chemotherapy 
We are aiming to increase the awareness of this new treatment and also to document the results of the patients received this treatment in the last few years until end of next year.</summary>
    <trialwebsite />
    <publication>Khalafallah AA, Loi SW, Love S, Mohamed M, Mace R, Khalil R, Girgs M, Raj R, Mathew M.
Early Application of High Cut-Off Haemodialysis for de-Novo Myeloma Nephropathy is Associated with Long-Term Dialysis-Independency and Renal Recovery. Mediterr J Hematol Infect Dis. 2013;5(1):e2013007. doi: 10.4084/MJHID.2013.007. Epub 2013 Jan 2. PMID: 23350020
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552781/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552781/pdf/mjhid-5-1-e2013007.pdf</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Tasmanian Human Research Ethics Committee</ethicname>
      <ethicaddress>University of Tasmania Private Bag 01 Hobart, Tas 7001 Australia</ethicaddress>
      <ethicapprovaldate>21/11/2011</ethicapprovaldate>
      <hrec>H12160</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Alhossain A. Khalafallah</name>
      <address>Launceston General Hospital Charles Street, Launceston, TAS 7250</address>
      <phone>+61373487111</phone>
      <fax>+61373487695</fax>
      <email>khalafallah@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor Alhossain A. Khalafallah</name>
      <address>Launceston General Hospital Charles Street, Launceston, TAS 7250</address>
      <phone>+61373487111</phone>
      <fax>+61373487695</fax>
      <email>khalafallah@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Alhossain A. Khalafallah</name>
      <address>Launceston General Hospital Charles Street, Launceston, TAS 7250</address>
      <phone>+61373487111</phone>
      <fax>+61373487695</fax>
      <email>khalafallah@dhhs.tas.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor Alhossain Khalafallah</name>
      <address>Launceston General Hospital 
Charles Street
TAS 7250 Australia
</address>
      <phone>+61367776777</phone>
      <fax />
      <email>khalafallah@dhhs.tas.gov.au </email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>